Sanofi 3Q Net Profit Up 6.8%; Raises '09 Target
30 10월 2009 - 4:22PM
Dow Jones News
French drugs company Sanofi-Aventis SA (SNY) Friday reported a
6.8% rise in third-quarter net profit due to robust sales growth of
blockbuster drugs Lantus and Lovenox, and raised full-year
guidance, citing an expected $500 million boost to fourth-quarter
sales from the swine flu vaccine.
The company increased full-year guidance to at least 11% growth
in adjusted earnings per share excluding selected items, up from
the previous target of 10%.
Sanofi Friday also said it is buying the French beauty nutrition
company Laboratoire Oenobiol to bolster its over-the-counter
offering in its latest step to find new sources of growth to offset
the threat of patent expiries.
Third-quarter net profit rose 6.8% to EUR1.42 billion compared
with EUR1.33 billion a year ago, the company said.
Sales rose 8% to EUR7.4 billion from EUR6.85 billion a year ago,
above analysts' estimates of EUR7.37 billion, according to a Dow
Jones Newswires survey of 14 analysts. Double-digit sales growth of
diabetes drug Lantus and blood thinner Lovenox helped offset a
steep drop in sales of cancer treatment Eloxatin, which were hit by
generics competition.
Lantus sales rose almost 22%, in a sign the company has managed
to successfully shrug off the idea the drug could be linked to
cancer. Eloxatin sales were down 44%, at constant exchange rates,
to EUR193 million, as generics competition in the U.S. and Europe
weighed on its performance. Generics competition to its Plavix
drug, which posted 4% sales growth at constant rates to EUR664
million, is expected to accelerate in the fourth quarter in Europe,
Chief Executive Chris Viehbacher told journalists.
Under the direction of Viehbacher, who is looking to emerging
markets to help fill the hole from future patent expiries, Sanofi
has bought companies specializing in vaccines and generics in
emerging markets.
Viehbacher is also pushing Sanofi to seek more partnerships to
fill its pipeline of new products after slimming down its R&D
operations and cutting a number of projects. In the past week,
Sanofi has signed agreements with two U.S.-based companies to
license treatments in the fields of cancer and diabetes.
Viehbacher repeated his line that the company is not pursuing a
large acquisition, and said Friday that an acquisition of over
EUR15 billion "is not on my radar screen."
U.K.-based rivals AstraZeneca PLC (AZN) and GlaxoSmithKline PLC
(GSK) also reported strong results this week. AstraZeneca got a
boost in pandemic flu vaccine sales over the quarter and Glaxo,
like Sanofi, said it expects sales of its H1N1 vaccine to lift
fourth-quarter business.
Sanofi shares have risen over 18% since the beginning of the
year, outpacing the CAC-40 Paris index.
- By Mimosa Spencer, Dow Jones Newswires; +33 1 40 17 17 73;
mimosa.spencer@dowjones.com